RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+5.31%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.63B
AUM Growth
+$2.63B
(-15%)
Cap. Flow
-$276M
Cap. Flow
% of AUM
-10.5%
Top 10 Holdings %
Top 10 Hldgs %
36.37%
Holding
119
New
10
Increased
38
Reduced
30
Closed
12
Top Buys
| 1 |
Scholar Rock
SRRK
|
$31M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$28.6M |
| 3 |
Tenet Healthcare
THC
|
$16.3M |
| 4 |
Amicus Therapeutics
FOLD
|
$12.7M |
| 5 |
Janux Therapeutics
JANX
|
$10.9M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$59.8M |
| 2 |
Humana
HUM
|
$46.9M |
| 3 |
Exact Sciences
EXAS
|
$39.2M |
| 4 |
Neurocrine Biosciences
NBIX
|
$29.8M |
| 5 |
Align Technology
ALGN
|
$29.1M |
Sector Composition
| 1 | Healthcare | 97.94% |
| 2 | Consumer Staples | 1.85% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Agios Pharmaceuticals
AGIO
$2.36B
| $15.5M | 0.59% |
471,086
-228,303
| -33% | -$7.5M |
|
52
Aclaris Therapeutics
ACRS
$223M
| $15.4M | 0.59% |
6,204,309
+3,450,814
| +125% | +$8.56M |
|
53
Crinetics Pharmaceuticals
CRNX
$3.26B
| $15M | 0.57% |
294,100
+4,700
| +2% | +$240K |
|
54
Pharvaris
PHVS
$1.41B
| $14.9M | 0.57% |
775,131
+18,200
| +2% | +$349K |
|
55
Agilon Health
AGL
$497M
| $14.2M | 0.54% |
7,463,300
-1,633,500
| -18% | -$3.1M |
|
56
Oscar Health
OSCR
$4.57B
| $14.1M | 0.54% |
1,050,000
+38,600
| +4% | +$519K |
|
|
SWTX
57
DELISTED
SpringWorks Therapeutics
SWTX
| $11.9M | 0.45% |
328,911
+129,056
| +65% | +$4.66M |
|
58
Dyne Therapeutics
DYN
$1.92B
| $11.2M | 0.43% |
474,528
+13,500
| +3% | +$318K |
|
|
59
Janux Therapeutics
JANX
$1.38B
| $10.9M | 0.42% |
+204,466
| New | +$10.9M |
|
|
INZY
60
DELISTED
Inozyme Pharma
INZY
| $10.7M | 0.41% |
3,861,983
+59,100
| +2% | +$164K |
|
61
Neumora Therapeutics
NMRA
$283M
| $10.1M | 0.39% |
955,106
+127,005
| +15% | +$1.35M |
|
62
Jasper Therapeutics
JSPR
$44.2M
| $9.9M | 0.38% |
463,088
+4,000
| +0.9% | +$85.5K |
|
63
Enliven Therapeutics
ELVN
$1.24B
| $9.64M | 0.37% |
428,571
| – | – |
|
64
Xencor
XNCR
$594M
| $9.22M | 0.35% |
401,013
| – | – |
|
65
Cullinan Oncology
CGEM
$456M
| $9.04M | 0.34% |
742,114
+5,200
| +0.7% | +$63.3K |
|
66
Prothena Corp
PRTA
$452M
| $8.93M | 0.34% |
644,601
+19,553
| +3% | +$271K |
|
67
Compass Therapeutics
CMPX
$466M
| $8.38M | 0.32% |
5,779,575
+150,336
| +3% | +$218K |
|
|
BCAX
68
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $7.77M | 0.3% |
445,975
| – | – |
|
69
Ardelyx
ARDX
$1.57B
| $7.42M | 0.28% |
+1,463,629
| New | +$7.42M |
|
|
ZBIO
70
Zenas BioPharma, Inc. Common Stock
ZBIO
$722M
| $7.2M | 0.27% |
878,667
| – | – |
|
71
Beam Therapeutics
BEAM
$1.9B
| $6.26M | 0.24% |
252,223
+2,300
| +0.9% | +$57K |
|
72
Tarsus Pharmaceuticals
TARS
$2.44B
| $6.14M | 0.23% |
+110,889
| New | +$6.14M |
|
|
NVRO
73
DELISTED
NEVRO CORP.
NVRO
| $6.13M | 0.23% |
1,648,100
+266,600
| +19% | +$992K |
|
74
Soleno Therapeutics
SLNO
$3.56B
| $5.58M | 0.21% |
+124,095
| New | +$5.58M |
|
75
Pliant Therapeutics
PLRX
$105M
| $5.33M | 0.2% |
404,796
+19,800
| +5% | +$261K |
|